Analysis of antithrombotic therapy of atrial fibrillation in international and Russian registries
https://doi.org/10.24411/2588-0519-2019-10066
Abstract
In the article the features of the organization of international and Russian registers of patients with atrial fibrillation (AF), the clinical and demographic characteristics of patients included in the registers, as well as the features of antithrombotic therapy of AF and its compliance with current clinical guidelines were observed. In a number of large randomized controlled trials (RCTs), not less effectiveness, and in some cases, the superiority of direct oral anticoagulants (DOACs) over warfarin, were proved in the prevention of ischemic insulin stroke patients with non-valvular AF with better safety profile and ease of use. However, the problem of the use of data obtained during RCTs in real clinical practice, for the solution of which medical registers are gaining much popularity, remains relevant. The article provides an analysis of 16 prospective multicenter international and Russian registers of patients with AF. For convenience of comparison, registers were divided into three groups in accordance with the features of the organization and inclusion criteria. Unambiguous conclusions were drawn about the incompatibility of the real clinical practice of antithrombotic therapy of AF with current clinical recommendations. Differences in the population of patients with AF in Russia compared with European countries were found, which led to the conclusion that insufficient detection of AF at the outpatient stage of diagnosis and the resulting inappropriate anticoagulant therapy aiming the prevention of stroke and ischemic complications take place, which may be due to the differences in the socioeconomic status of the regions and the characteristics of the organization of medical treatment and preventive care to the population.
About the Authors
O. V. Reshetko
Saratov Medical University named after V.I. Razumovsky
Russian Federation
Russian Federation
MD, professor, Head of Department of Pharmacology
Saratov
A. V. Sokolov
Saratov Medical University named after V.I. Razumovsky
Russian Federation
Russian Federation
postgraduate student of Department of Pharmacology
Saratov
N. V. Furman
Saratov Medical University named after V.I. Razumovsky
Russian Federation
Russian Federation
PhD, Head of Emergency Cardiology Department, Research
Institute of Cardiology
Saratov
References
1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215. DOI: 10.1161/CIRCULATIONAHA.109.192667.
2. Bjorck S, Palaszewski B, Friberg L, Bergfeldt L. Atrialfi brillation, strokerisk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44(11):3103—8. DOI: 10.1161/STROKEAHA.113.002329.
3. Steff el J, Verhamme P, Potpara TS, et al. Th e 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fi brillation. Eur Heart J. 2018;9(16):1330—1393. DOI: 10.1093/eurheartj/ehy136.
4. Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fi brillation. J Am Heart Assoc. 2015;21;4(1):e001486. DOI: 10.1161/JAHA.114.001486.
5. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fi brillation in the EuropeanUnion, from 2000 to 2060. Eur Heart J. 2013;34(35):2746—51. doi: 10.1093/eurheartj/eht280. Conen D Epidemiology of Atrial Fibrillation. Eur Heart J. 2018;39(16):1323—1324. DOI: 10.1093/eurheartj/ehy171.
6. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215. DOI: 10.1161/CIRCULATIONAHA.109.192667.
7. Proietti M, Laroche C, Nieuwlaat R, et al. Increased burden of comorbidities and risk of cardiovascular death in atrial fi brillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. Eur J Intern Med. 2018;55:28—34. DOI: 10.1016/j.ejim.2018.05.016.
8. Steff el J, Verhamme P, Potpara TS, et al. Th e 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fi brillation. Eur Heart J. 2018;9(16):1330—1393. DOI: 10.1093/eurheartj/ehy136.
9. Gadsbøll K, Staerk L, Fosbøl EL, et al. Increased use of oral anticoagulants in patients with atrial fi brillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017;38(12):899—906. DOI: 10.1093/eurheartj/ehw658.
10. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fi brillation in the EuropeanUnion, from 2000 to 2060. Eur Heart J. 2013;34(35):2746—51. doi: 10.1093/eurheartj/eht280. Conen D Epidemiology of Atrial Fibrillation. Eur Heart J. 2018;39(16):1323—1324. DOI: 10.1093/eurheartj/ehy171.
11. Cowan JC, Wu J, Hall M, et al. A 10 year study of hospitalized atrial fi brillation-related stroke in England and its association with uptake of oral anticoagulation. Eur Heart J. 2018;39(32):2975—2983. DOI: 10.1093/eurheartj/ehy411.
12. Proietti M, Laroche C, Nieuwlaat R, et al. Increased burden of comorbidities and risk of cardiovascular death in atrial fi brillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. Eur J Intern Med. 2018;55:28—34. DOI: 10.1016/j.ejim.2018.05.016.
13. Camm AJ, Accetta G, Ambrosio G, et al for the GARFIELD-AF Investigators. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fi brillation. Heart. 2017;103:307—314. http://dx.doi.org/10.1136/heartjnl-2016-309832.
14. Gadsbøll K, Staerk L, Fosbøl EL, et al. Increased use of oral anticoagulants in patients with atrial fi brillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017;38(12):899—906. DOI: 10.1093/eurheartj/ehw658.
15. Apenteng PN, Gao H, Hobbs FDR, et al. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fi brillation: fi ndings from the GARFIELD-AF registry. BMJOpen. 2018;8:e018905. DOI:10.1136/bmjopen-2017-018905.
16. Cowan JC, Wu J, Hall M, et al. A 10 year study of hospitalized atrial fi brillation-related stroke in England and its association with uptake of oral anticoagulation. Eur Heart J. 2018;39(32):2975—2983. DOI: 10.1093/eurheartj/ehy411.
17. Papp J, Zima E, Bover R, et al. Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry. European Heart Journal — Cardiovascular Pharmacotherapy. 2017;3:147—150, https://doi.org/10.1093/ehjcvp/pvx003.
18. Camm AJ, Accetta G, Ambrosio G, et al for the GARFIELD-AF Investigators. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fi brillation. Heart. 2017;103:307—314. http://dx.doi.org/10.1136/heartjnl-2016-309832.
19. Fletchtr R, Fletcher C, Vagner E. Clinical epidemiology. Basics of the evidence-based medicine. Moscow: Media Sphere; 1998. (in Russ).
20. Apenteng PN, Gao H, Hobbs FDR, et al. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fi brillation: fi ndings from the GARFIELD-AF registry. BMJOpen. 2018;8:e018905. DOI:10.1136/bmjopen-2017-018905.
21. Stanley K. Evaluation of randomized controlled trials. Circulation. 2007;115(13):1819—22. DOI: 10.1161/CIRCULATIONAHA.106.618603.
22. Papp J, Zima E, Bover R, et al. Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry. European Heart Journal — Cardiovascular Pharmacotherapy. 2017;3:147—150, https://doi.org/10.1093/ehjcvp/pvx003.
23. Connolly SJ, Ezekowitz MD, Yusuf S, at al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fi brillation. N Engl J Med. 2009;361:1139—51. DOI: 10.1056/NEJMoa0905561.
24. Fletchtr R, Fletcher C, Vagner E. Clinical epidemiology. Basics of the evidence-based medicine. Moscow: Media Sphere; 1998. (in Russ).
25. Stanley K. Evaluation of randomized controlled trials. Circulation. 2007;115(13):1819—22. DOI: 10.1161/CIRCULATIONAHA.106.618603.
26. Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fi brillation. N Engl J Med. 2011;365:981—992. DOI: 10.1056/NEJMoa1107039.
27. Connolly SJ, Ezekowitz MD, Yusuf S, at al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fi brillation. N Engl J Med. 2009;361:1139—51. DOI: 10.1056/NEJMoa0905561.
28. Patel MR, Mahaff ey KW, Garg J, Pan G, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fi brillation. N Engl J Med. 2011;365:883—891. DOI: 10.1161/CIRCULATIONAHA.
29. Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fi brillation. N Engl J Med. 2011;365:981—992. DOI: 10.1056/NEJMoa1107039.
30. Steff el J, Verhamme P, Potpara TS, et al. Th e 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fi brillation. Eur Heart J. 2018;39(16):1330—1393. DOI: 10.1093/eurheartj/ehy136.
31. Patel MR, Mahaff ey KW, Garg J, Pan G, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fi brillation. N Engl J Med. 2011;365:883—891. DOI: 10.1161/CIRCULATIONAHA.
32. Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fi brillation. Cochrane Database of Systematic Reviews. 2018 Mar 6;3:CD008980. DOI: 10.1002/14651858.CD008980.pub3.
33. Steff el J, Verhamme P, Potpara TS, et al. Th e 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fi brillation. Eur Heart J. 2018;39(16):1330—1393. DOI: 10.1093/eurheartj/ehy136.
34. Yao X, Abraham NS, Alexander GC, et al. Eff ect ofAdherence to OralAnticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc. 2016;5(2):e003074. DOI: 10.1161/JAHA.115.003074.
35. Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fi brillation. Cochrane Database of Systematic Reviews. 2018 Mar 6;3:CD008980. DOI: 10.1002/14651858.CD008980.pub3.
36. Gliklich RE, Dreyer NA. Registries for evaluating patient outcomes: a user’s guide. 2nd ed. Rockville: Agency for Healthcare Research and Quality (US); 2010.
37. Yao X, Abraham NS, Alexander GC, et al. Eff ect ofAdherence to OralAnticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc. 2016;5(2):e003074. DOI: 10.1161/JAHA.115.003074.
38. Martsevich SY, Kutishenko NP. Randomised Clinical Trials and Observational Studies: the Ratio in the Hierarchy of Evidence of the Effi cacy of Drugs. Racionalʹnaâ Farmakoterapiâ v Kardiologii. 2016; 12(5):567—573. (In Russ).DOI:10.20996/1819-6446-2016-12-5-567-573.
39. Gliklich RE, Dreyer NA. Registries for evaluating patient outcomes: a user’s guide. 2nd ed. Rockville: Agency for Healthcare Research and Quality (US); 2010.
40. Fanaroff AC, Steff el J, Alexander JH, et al. Stroke prevention in atrial fi brillation: re-defi ning ‘real-world data’ within the broader data universe. Eur Heart J. 2018;39:2932—2941 https://doi.org/10.1093/eurheartj/ehy236.
41. Martsevich SY, Kutishenko NP. Randomised Clinical Trials and Observational Studies: the Ratio in the Hierarchy of Evidence of the Effi cacy of Drugs. Racionalʹnaâ Farmakoterapiâ v Kardiologii. 2016; 12(5):567—573. (In Russ).DOI:10.20996/1819-6446-2016-12-5-567-573.
42. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fi brillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26:2422—2434.
43. Fanaroff AC, Steff el J, Alexander JH, et al. Stroke prevention in atrial fi brillation: re-defi ning ‘real-world data’ within the broader data universe. Eur Heart J. 2018;39:2932—2941 https://doi.org/10.1093/eurheartj/ehy236.
44. Haeusler KG, Gerth A, Limbourg T, et al. Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany — results from the German AFNET registry. BMC Neurol. 2015;5(15):129. DOI: 10.1186/s12883-015-0371-8.
45. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fi brillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26:2422—2434.
46. Nabauer M, Gerth A, Limbourg T, et al. Th e Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11:423—34. DOI: 10.1093/europace/eun369.
47. Haeusler KG, Gerth A, Limbourg T, et al. Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany — results from the German AFNET registry. BMC Neurol. 2015;5(15):129. DOI: 10.1186/s12883-015-0371-8.
48. Kirchhof P, Schmalowsky J, Pittrow D, Rosin L, Kirch W, Wegscheider K, Meinertz T. Management of patients wtih atrial fi brillation by primary care physicians in Germany: 1-year results of the ATRIUM registry. ClinCardio. 2014;37:277—284. doi: 10.1002/clc.22272.
49. Nabauer M, Gerth A, Limbourg T, et al. Th e Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11:423—34. DOI: 10.1093/europace/eun369.
50. Huisman MV, Ma CS, Diener HC, et al. Antithrombotic therapy use in patients with atrial fi brillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. Europace. 2016;18(9):1308—18. DOI: 10.1093/europace/euw073.
51. Kirchhof P, Schmalowsky J, Pittrow D, Rosin L, Kirch W, Wegscheider K, Meinertz T. Management of patients wtih atrial fi brillation by primary care physicians in Germany: 1-year results of the ATRIUM registry. ClinCardio. 2014;37:277—284. doi: 10.1002/clc.22272.
52. Mazurek M, Huisman MV, Rothman KJ, et al. Regional Diff erences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIAAF Phase II Registry. Th rombHaemost. 2017 Dec;117(12):2376—2388. DOI: 10.1160/TH17-08-0555.
53. Huisman MV, Ma CS, Diener HC, et al. Antithrombotic therapy use in patients with atrial fi brillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. Europace. 2016;18(9):1308—18. DOI: 10.1093/europace/euw073.
54. Piccini JP, Fraulo ES, Ansell JE, et al. Outcomes registry for better informed treatment of atrial fi brillation: rationale and design of ORBIT-AF. Am Heart J. 2011;162(4):606—612.
55. Mazurek M, Huisman MV, Rothman KJ, et al. Regional Diff erences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIAAF Phase II Registry. Th rombHaemost. 2017 Dec;117(12):2376—2388. DOI: 10.1160/TH17-08-0555.
56. Cullen MW, Kim S, Piccini JP Sr, Ansell JE, et al. Risks and benefi ts of anticoagulation in atrial fi brillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. CircCardiovascQualOutcomes. 2013;6(4):461—9. DOI: 10.1161/CIRCOUTCOMES.113.000127.
57. Piccini JP, Fraulo ES, Ansell JE, et al. Outcomes registry for better informed treatment of atrial fi brillation: rationale and design of ORBIT-AF. Am Heart J. 2011;162(4):606—612.
58. Steinberg BA, Blanco RG, Ollis D, et al. Outcomes registry for better informed treatment of atrial fi brillation II: rationale and design of the ORBITAF II registry. Am Heart J. 2014;168(2):160-7. DOI: 10.1016/j.ahj.2014.04.005.
59. Cullen MW, Kim S, Piccini JP Sr, Ansell JE, et al. Risks and benefi ts of anticoagulation in atrial fi brillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. CircCardiovascQualOutcomes. 2013;6(4):461—9. DOI: 10.1161/CIRCOUTCOMES.113.000127.
60. Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fi brillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163(1):13—19 e1. DOI: 10.1016/j.ahj.2011.09.011.
61. Steinberg BA, Blanco RG, Ollis D, et al. Outcomes registry for better informed treatment of atrial fi brillation II: rationale and design of the ORBITAF II registry. Am Heart J. 2014;168(2):160-7. DOI: 10.1016/j.ahj.2014.04.005.
62. Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fi brillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORPAF) Long-Term General Registry. Europace. 2018; 1;20(5):747—757. DOI: 10.1093/europace/eux301.
63. Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fi brillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163(1):13—19 e1. DOI: 10.1016/j.ahj.2011.09.011.
64. Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fi brillation in seven European countries aft er the publication of the 2010 ESC Guidelines on atrial fi brillation: primary results of the PREventionoF thromboembolic events—European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014;16(1):6—14. DOI: 10.1093/europace/eut263.
65. Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fi brillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORPAF) Long-Term General Registry. Europace. 2018; 1;20(5):747—757. DOI: 10.1093/europace/eux301.
66. Boytsov SA, Luk’yanov MM, Yakushin SS, et al. Cardiovascular diseases registry (RECVAZA): diagnostics, concomitant cardiovascular pathology, comorbidities and treatment in the real outpatient-polyclinic practice. Cardiovascular Th erapy and Prevention. 2014;13(6):44—50. (In Russ).] https://doi.org/10.15829/1728-8800-2014-6-3-8.
67. Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fi brillation in seven European countries aft er the publication of the 2010 ESC Guidelines on atrial fi brillation: primary results of the PREventionoF thromboembolic events—European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014;16(1):6—14. DOI: 10.1093/europace/eut263.
68. Stepina EV, Lukyanov MM, Bichurina MA, et al. Prescription of medications infl uencing prognosis in atrial fi brillation with arterial hypertension, coronary heart disease, chronic heart failure, by the registry REKVAZA-CLINIC. Cardiovascular Th erapy and Prevention. 2017;16(2):33—38. (In Russ). https://doi.org/10.15829/1728-8800-2017-2-33-38.
69. Boytsov SA, Luk’yanov MM, Yakushin SS, et al. Cardiovascular diseases registry (RECVAZA): diagnostics, concomitant cardiovascular pathology, comorbidities and treatment in the real outpatient-polyclinic practice. Cardiovascular Th erapy and Prevention. 2014;13(6):44—50. (In Russ).] https://doi.org/10.15829/1728-8800-2014-6-3-8.
70. Mihin VP, Maslennikova YV, Luk’yanov MM. Struktura gospitalizacii i antitromboticheskaya terapiya u bol’nyh fi brillyaciej predserdij v sochetanii s ishemicheskoj bolezn’yu serdca (dannye registra REKVAZA FPKursk). Arhiv» vnutrennej mediciny. 2017;7(3):217—223. (In Russ).
71. Stepina EV, Lukyanov MM, Bichurina MA, et al. Prescription of medications infl uencing prognosis in atrial fi brillation with arterial hypertension, coronary heart disease, chronic heart failure, by the registry REKVAZA-CLINIC. Cardiovascular Th erapy and Prevention. 2017;16(2):33—38. (In Russ). https://doi.org/10.15829/1728-8800-2017-2-33-38.
72. Yakusevich VV, Pozdnyakova EM, Yakusevich V, et al. An outpatient with atrial fi brillation: key features. Th e fi rst data of REKVAZA FP — Yaroslavl register. Rational Pharmacotherapy in Cardiology. 2015;11(2):149—152. (In Russ).] https://doi.org/10.20996/1819-6446-2015-11-2-149-152.
73. Mihin VP, Maslennikova YV, Luk’yanov MM. Struktura gospitalizacii i antitromboticheskaya terapiya u bol’nyh fi brillyaciej predserdij v sochetanii s ishemicheskoj bolezn’yu serdca (dannye registra REKVAZA FPKursk). Arhiv» vnutrennej mediciny. 2017;7(3):217—223. (In Russ).
74. Martsevich SY, Navasardian AR, Kutishenko NP, et al. Studying atrial fi brillation on the basis of the “PROFILE” registry. Cardiovascular Th erapy and Prevention. 2014;13(2):35-39. (In Russ).] https://doi.org/10.15829/1728-8800-2014-2-35-39.
75. Yakusevich VV, Pozdnyakova EM, Yakusevich V, et al. An outpatient with atrial fi brillation: key features. Th e fi rst data of REKVAZA FP — Yaroslavl register. Rational Pharmacotherapy in Cardiology. 2015;11(2):149—152. (In Russ).] https://doi.org/10.20996/1819-6446-2015-11-2-149-152.
76. Korennova OY, Mal’cev SN, Petrenko AV, Bulahova EY. Fibrillyaciya predserdij v real’noj klinicheskoj praktike: uroki odnogo regional’nogo registra. Trudnyj pacient. 2015;13(4):8—11. (In Russ).
77. Martsevich SY, Navasardian AR, Kutishenko NP, et al. Studying atrial fi brillation on the basis of the “PROFILE” registry. Cardiovascular Th erapy and Prevention. 2014;13(2):35-39. (In Russ).] https://doi.org/10.15829/1728-8800-2014-2-35-39.
78. Martsevich SY, Ginsburg ML, Kutishenko NP, et al. Lyubertsy Study of mortality in patients with acute myocardial infarction (LIS): the analysis of anamnestic predictors of in-hospital mortality. Cardiovascular Th erapy and Prevention. 2012;11(1):45—48. (In Russ).
79. Korennova OY, Mal’cev SN, Petrenko AV, Bulahova EY. Fibrillyaciya predserdij v real’noj klinicheskoj praktike: uroki odnogo regional’nogo registra. Trudnyj pacient. 2015;13(4):8—11. (In Russ).
80. Martsevich S.Y., Kutishenko N., Suvorov AY, at al. Characteristics of patients with cerebral stroke or transient ischemic attack, included into the LIS-2 register (Lyubertsy study of mortality in patients aft er stroke). Rational Pharmacotherapy in Cardiology. 2015;11(1):18—24. (In Russ). https://doi.org/10.20996/1819-6446-2015-11-1-18-24.
81. Martsevich SY, Ginsburg ML, Kutishenko NP, et al. Lyubertsy Study of mortality in patients with acute myocardial infarction (LIS): the analysis of anamnestic predictors of in-hospital mortality. Cardiovascular Th erapy and Prevention. 2012;11(1):45—48. (In Russ).
82. Shlyakhto EV, EzhovАV, Zenin SА, et al Clinical portrait of the atrial fi brillation patient in Russian Federation. Data from the global registry GLORIA AF. Russ J Cardiol. 2017;9(149):21—27. (In Russ). http://dx.doi.org/10.15829/1560-4071-2017-9-21-27.
83. Martsevich S.Y., Kutishenko N., Suvorov AY, at al. Characteristics of patients with cerebral stroke or transient ischemic attack, included into the LIS-2 register (Lyubertsy study of mortality in patients aft er stroke). Rational Pharmacotherapy in Cardiology. 2015;11(1):18—24. (In Russ). https://doi.org/10.20996/1819-6446-2015-11-1-18-24.
84. Ruiz Ortiz M, Muñiz J, Raña Míguez P, at al. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace. 2018;20(10):1577—1583. DOI: 10.1093/europace/eux316.
85. Shlyakhto EV, EzhovАV, Zenin SА, et al Clinical portrait of the atrial fi brillation patient in Russian Federation. Data from the global registry GLORIA AF. Russ J Cardiol. 2017;9(149):21—27. (In Russ). http://dx.doi.org/10.15829/1560-4071-2017-9-21-27.
86. Sato T, Aizawa Y, Fuse K et al. Th e Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry. J Stroke Cerebrovasc Dis. 2018;27(11):3280—3288. DOI: 10.1016/j.jstrokecerebrovasdis.2018.07.028.
87. Ruiz Ortiz M, Muñiz J, Raña Míguez P, at al. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace. 2018;20(10):1577—1583. DOI: 10.1093/europace/eux316.
88. Steinberg BA, Shrader P, Th omas L, et al. Off -label dosing of nonvitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am CollCardiol. 2016; 68:2597—604. http://dx.doi.org/10.1016/j.jacc.2016.09.966
89. Sato T, Aizawa Y, Fuse K et al. Th e Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry. J Stroke Cerebrovasc Dis. 2018;27(11):3280—3288. DOI: 10.1016/j.jstrokecerebrovasdis.2018.07.028.
90. Boytsov SA, Martsevich SYu, Loukianov MM, et al. Outpatient register of cardiovascular diseases in the Ryazan region (RECVASA): principal tasks, experience of development and fi rst results. Rational Pharmacother. Card. 2013;9(1):4—14. (In Russ). https://doi.org/10.15829/1728-8800-2015-1-53-62.
91. Steinberg BA, Shrader P, Th omas L, et al. Off -label dosing of nonvitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am CollCardiol. 2016; 68:2597—604. http://dx.doi.org/10.1016/j.jacc.2016.09.966
92. Gaisenok OV, Leonov AS. Th e use of oral anticoagulants in patients with atrial fi brillation: cohort study data. Ration Pharmacother. Cardiol. 2016;12(4):376—379. (In Russ).] DOI: http://dx.doi.org/10.20996/1819-6446-2016-12-4-376-379.
93. Boytsov SA, Martsevich SYu, Loukianov MM, et al. Outpatient register of cardiovascular diseases in the Ryazan region (RECVASA): principal tasks, experience of development and fi rst results. Rational Pharmacother. Card. 2013;9(1):4—14. (In Russ). https://doi.org/10.15829/1728-8800-2015-1-53-62.
94. Boytsov SA, Samorodskaya IV, Tretyakov VV Gradient of Mortality of Persons Aged 40—59 in Regions of the Russian Federation Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. Annals of the Russian Academy of Medical Sciences. 2014;7—8:106—111. (In Russ).] URL: http://cyberleninka.ru/article/n/gradient-smertnosti-naseleniya-v-vozraste-40-59-let-v-subektah-rossiyskoyfederatsii (дата обращения: 06.01.2017).
95. Gaisenok OV, Leonov AS. Th e use of oral anticoagulants in patients with atrial fi brillation: cohort study data. Ration Pharmacother. Cardiol. 2016;12(4):376—379. (In Russ).] DOI: http://dx.doi.org/10.20996/1819-6446-2016-12-4-376-379.
96. Pogosova NV, Oganov RG, Suvorov SV. Why cardiovascular mortality in Moscow is lower than in other regions of the Russian Federation? Cardiovascular Th erapy and Prevention. 2015;14(2):4—12. (In Russ). DOI:10.15829/1728-8800-2015-2-4-12.
97. Boytsov SA, Samorodskaya IV, Tretyakov VV Gradient of Mortality of Persons Aged 40—59 in Regions of the Russian Federation Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. Annals of the Russian Academy of Medical Sciences. 2014;7—8:106—111. (In Russ).] URL: http://cyberleninka.ru/article/n/gradient-smertnosti-naseleniya-v-vozraste-40-59-let-v-subektah-rossiyskoyfederatsii (дата обращения: 06.01.2017).
98. Mazurek M, Huisman MV, Rothman KJ et al. Regional Diff erences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIAAF Phase II Registry. Th rombHaemost. 2017;117:2376—2388. DOI:https://doi.org/10.1160/TH17-08-0555.
99. Pogosova NV, Oganov RG, Suvorov SV. Why cardiovascular mortality in Moscow is lower than in other regions of the Russian Federation? Cardiovascular Th erapy and Prevention. 2015;14(2):4—12. (In Russ). DOI:10.15829/1728-8800-2015-2-4-12.
100. Steff el J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fi brillation. Eur Heart J. 2018;39(16):1330—1393. DOI: 10.1093/eurheartj/ehy136.
101. Mazurek M, Huisman MV, Rothman KJ et al. Regional Diff erences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIAAF Phase II Registry. Th rombHaemost. 2017;117:2376—2388. DOI:https://doi.org/10.1160/TH17-08-0555.
102. Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with nonvalvular atrial fi brillation: part 1. Eur Heart J. 2017;38(12):852—859. DOI: 10.1093/eurheartj/ehv643.
103. Steff el J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fi brillation. Eur Heart J. 2018;39(16):1330—1393. DOI: 10.1093/eurheartj/ehy136.
104. Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with nonvalvular atrial fi brillation: part 2. Eur Heart J. 2017;21;38(12):860-868. DOI: 10.1093/eurheartj/ehw069.
105. Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with nonvalvular atrial fi brillation: part 1. Eur Heart J. 2017;38(12):852—859. DOI: 10.1093/eurheartj/ehv643.
106. Chernov AA, Kleymenova EB, Sychev DA, et al. Physician’s Adherence to Clinical Guidelines for in-Hospital Anticoagulant Prescribing. Rational Pharmacotherapy in Cardiology. 2018;14(4):501—508. (In Russ). DOI: 10.20996/1819-6446-2018-14-4-501-508
107. Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with nonvalvular atrial fi brillation: part 2. Eur Heart J. 2017;21;38(12):860-868. DOI: 10.1093/eurheartj/ehw069.
108. escardio.org [Internet]. European Society of Cardiology. Atrial Fibrillation III (AF III) Registry. Available from: https://www.escardio.org/Research/Registries-&-surveys/Observational-research-programme/atrialfibrillation-3-registry.
109. Chernov AA, Kleymenova EB, Sychev DA, et al. Physician’s Adherence to Clinical Guidelines for in-Hospital Anticoagulant Prescribing. Rational Pharmacotherapy in Cardiology. 2018;14(4):501—508. (In Russ). DOI: 10.20996/1819-6446-2018-14-4-501-508
110. escardio.org [Internet]. European Society of Cardiology. Atrial Fibrillation III (AF III) Registry. Available from: https://www.escardio.org/Research/Registries-&-surveys/Observational-research-programme/atrialfibrillation-3-registry.
Review
For citations:
Reshetko O.V., Sokolov A.V., Furman N.V. Analysis of antithrombotic therapy of atrial fibrillation in international and Russian registries. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2019;(1):83-96. (In Russ.) https://doi.org/10.24411/2588-0519-2019-10066
Views:
1014
Email this article 